Community Insights on Treating High-Risk NMIBC

Neal D. Shore, MD, FACS, and Chandler Park, MD, share how the POTOMAC data, and a newly FDA-approved combination, are opening up shared decision-making with patients.

Neal D. Shore, MD, FACS, walks through exactly how POTOMAC's design showed durvalumab (Imfinzi) plus BCG improved disease-free survival in NMIBC.

Chandler Park, MD, and Neal D. Shore, MD, FACS, trace immune-related adverse events from melanoma's early days to today's playbook for community urology.

Neal D. Shore, MD, FACS, and Chandler Park, MD, further discuss POTOMAC data, including a 37% lower rate of cystectomy, subgroup HRs as low as 0.48, and 5-year OS data with no detriment.

Chandler Park, MD, and Neal D. Shore, MD, FACS, hand community practices a concrete playbook for offering immunotherapy with BCG.